Adam Zamecnik

Only days after the EU-wide decentralized approval of Adalvo's Victoza generic, Newbury broke news with the greenlighting of its own Victoza rival in Denmark.

Following on from the recently announced closing of a Saudi Arabia-focused fund, TVM Capital has doubled down on its local efforts with a further $35m investment into Boston Oncology Arabia's efforts.

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

After announcing a pivot to innovative oncology treatments from biosimilars, Coherus has granted an exclusive license for its novel biologic cancer therapy Loqtorzi to Apotex in Canada.

ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.

Marking a further development in the story of Hyloris' in-licensing deal with QliniQ, the company's board has announced significant leadership and organizational changes to address potential concerns.

Following on from a flurry of deal and launches, Hikma has released another product onto the US market with the first of its sodium acetate injections, bolstered by 180 days of Competitive Generic Therapy exclusivity.

Marking the firm's second launch of a 505(b)(2) injectable this year, Amneal has released Focinvez in the US as an antiemetic agent used in chemotherapy regimens.

Despite doubling down on its rare disease ambitions with its Alimera acquisition earlier in July, ANI just announced the second US launch of a generic this month.

Following its recently announced leadership changes, Hyloris has made two announcements linked to the marketing of its combined pain therapy Maxigesic IV in Brazil and the US.